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The Philippine archipelago is rich in marine biodiversity and resources that are widely unexplored. Its
marine sediments harbor marine microbes that possess secondary metabolites with potent bioactivities.
This study aims to determine the antiproliferative activity of the crude extracts of selected Actinomycete
isolates (DSD011, DSD017, and DSD042) from Islas de Gigantes, Carles, Iloilo. The antiproliferative
screening was done using Saccharomyces cerevisiae as a model organism. Crude extracts of isolates
that are active in inhibiting the growth of S. cerevisiae were determined using the broth microdilution
method. Afterward, the active extract was tested using antiproliferative and budding yeast assays.
With the antiproliferative model, only DSD011 was found to inhibit the growth of S. cerevisiae. The
percentage of live and dead cells in DSD011 was comparable to those treated with Triton X (positive
control). Further, the budding yeast analysis showed that DSD011 induced G1 cell cycle arrest of
nearly 50% of S. cerevisiae cells. Thus, DSD011, a marine sediment-derived Actinomycete, serves as a
potential source of naturally occurring bioactive compounds with antiproliferative properties.
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INTRODUCTION
Cancer remains as one of the most lethal and widespread
diseases worldwide. In 2020, cancer incidence reached
19.3 million new cases and 10.0 million new deaths, with
lung cancer as the most prevalent (Sung et al., 2021).
The ability of metastatic cancer cells to develop ways
of resisting or avoiding the action of chemotherapeutic
agents aggravate the problem posed by cancer to global
health. Most treatment outcomes remain inadequate
despite the progress made in developing various
treatment strategies involving chemotherapeutic
agents (Asati et al., 2014). Due to this, new classes of
chemotherapeutic substances with much more selective
action against cancer cells are urgently needed (Trotsko
et al., 2018).
An intensive search for anticancer drugs in the last 50
years pointed to soil bacteria as a reliable source of novel
compounds with pharmaceutical potential (Mohr, 2016).
Forty-five percent of currently known microbial secondary
metabolites come from Actinomycetes, particularly in the
genus Streptomyces (Dalisay et al., 2013). Many of these
metabolites possess potent anticancer activity against
various cancer cell lines (Chen et al., 2018). However,
recent discoveries of novel pharmaceuticals from
Streptomyces have drastically decreased (Kemung et al.,

2018). The steady decrease in the number of developed
and approved pharmaceutical substances poses a serious
problem as there are increasing incidences of anticancer
resistance. Alternative approaches for developing drugs
from microbes are urgently needed due to the worsening
problem of anticancer resistance. One such approach is
the isolation of microbes from underexplored ecosystems
such as desert biomes and marine ecosystems.
Marine microorganisms are a prolific source of novel
compounds with varying chemical structures, many
of which exhibit bioactivities such as anticancer or
antitumor activity (Butler et al., 2013). Among these
microorganisms are marine Actinomycetes that produce
secondary metabolites of varying structural classes.
Besides being widely abundant in soil, Actinomycetes
also have a wide distribution in the ocean, from shallow
sea bodies to deep-sea sediments (Chen et al., 2016). In
the recent years, bacteria dwelling in marine sediments
have become the focus of many for the investigation
of possible sources of novel bioactive compounds
(Dalisay et al., 2013). Exploring this new source of
microorganisms resulted in the discovery of Salinispora,
a new taxon of obligate marine Actinomycetes (Kim et
al., 2020). Members of this genus possess extraordinary
biosynthetic diversity, as evident in their secondary
metabolite biosynthetic gene clusters (SMBGC) (Xu et
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al., 2019). The existence of these remarkable SMBGCs in
the genome of marine Actinomycetes was linked to their
functional adaptation in their distinct niche and habitat
(Penn et al., 2009). These SMBGCs provide specialized
metabolism to marine Actinomycetes, positing them as a
potential source of novel bioactive compounds (Letzel et
al., 2017). Salinosporamide A, an irreversible proteasome
inhibitor isolated from the actinomycete Salinospora
tropica, accomplished a series of phase I clinical trials
to treat multiple myeloma and other hematologic
malignancies (Kim et al., 2020). Furthermore, the
current investigation of secondary metabolites from
actinomycetes of the genus Nocardiopsis, Streptomyces,
and Micromonospora yielded promising bioactive
compounds (Kim et al., 2018).
In response to the health crisis posed by cancer worldwide,
marine sediments were collected from selected locations
of Islas de Gigantes, Iloilo, as a source of marine-derived
Actinomycetes. Marine Actinomycetes were isolated
from the sediment samples and their crude extracts were
screened against Saccharomyces cerevisiae. Budding
yeast bioassay using S. cerevisiae is an established
method useful for the preliminary screening for potential
anticancer compounds (Sanchez-Pico et al., 2014).
Budding yeast possesses cellular processes that are
remarkably homologous to mammalian cells (Matuo
et al., 2012). Eukaryotic cellular components such as
actin (Akram et al., 2020) and telomerase (Armstrong
& Tomita, 2017) are remained relatively unchanged
between yeasts and human cells. Furthermore,
antiproliferative compounds, such as tamoxifen (Yao et
al. 2020), stevioside (Boonkaewwan et al., 2013), and
lyc (Bertoli et al., 2013) were successfully identified
using yeast-based screening assays. Thus, the current
study used budding yeast bioassay to explore the
antiproliferative activity of selected marine sedimentderived Actinomycetes isolated from Islas de Gigantes,
Iloilo.
METHODS
Collection of marine sediments and culture isolation
of Actinomycetes
Marine sediment samples were collected from the vicinity
of Islas de Gigantes Carles, Iloilo through SCUBA diving
at depths of 20 to 30 m from the sea surface. Sample
collection was done by digging at least around 30 cm
below the seafloor. Processing and inoculation of the
marine sediment sample were performed as described
by the methods of Sabido et al. (2020). The marine
sediments were air-dried inside a biosafety cabinet and
then processed using dry stamp and heat shock methods.
Processed samples were inoculated in a solid marine
medium (ISP4, Difco dissolved in filtered seawater) and
incubated at room temperature (25°C- 28°C) for 15-30
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days. The growth of Actinomycetes was confirmed by
the presence of filamentous hyphae and/or the formation
of tough, leathery colonies on the agar surface. Single
colonies of Actinomycetes were isolated to pure cultures
on enriched marine media (Dalisay et al. 2013).
Preparation of Actinomycetes crude extracts
Three (3) isolates from the marine sediment samples
were investigated for antiproliferative activity using S.
cerevisiae. These Actinomycete isolates were designated
as DSD011, DSD017, and DSD042. The isolates were
inoculated and allowed to grow in marine medium
1 (MM1) agar (Dalisay et al., 2013). The isolates
inoculated in the MM1 agar were incubated for 14 days
at 25-28°C. After the incubation period, the biomass of
each isolate was harvested. The agar with the biomass
was then extracted thrice with ethyl acetate. The extracts
were then concentrated using a rotary evaporator and
dried in a vacuum. The dried extracts were reconstituted
in 100% dimethyl sulfoxide (DMSO) (100 mg/ml) and
stored at -80°C freezer until tested for antiproliferative
activity.
Preliminary screening for the antiproliferative
activity of the crude extracts
A 24 h broth culture of S. cerevisiae ATCC 20784 (0.5
OD cell density at 620 nm) was prepared and exposed
to different treatments as follows: dimethyl sulfoxide
(negative control), Triton X-100 (positive control), and
the reconstituted crude extracts of DSD011, DSD017,
and DSD042. Five (5) μL of each extract (stock solution
of 100 mg/ml) and controls were dispensed in separate
wells in the 96-wells microtiter plate and added with
195 μL of the seed culture. The prepared plates were
then incubated for 24 hours at 37 oC. After incubation,
each plate was read using a Multiskan FC Microplate
Photometer (Thermo Fisher Scientific, USA) at 620 nm.
The color-corrected Optical Density (OD) and percentage
growth inhibition (%GI) of the treatments and controls
were computed (Myers et al., 2013). Crude extracts with
%GI values of more than 50% were considered active
and subjected to further testing.
Antiproliferation assay
A 24 h broth culture of S. cerevisiae was harvested through
centrifugation at 8,000 rpm, washed with phosphatebuffered saline (PBS) pH 7.0 twice, and resuspended
with 195 µl PBS. The seed suspension was adjusted to
0.5 OD cell density at 620 nm. The seed suspension was
exposed to 5 µl of each extract with a final concentration
of 2500 µg/ml. Triton X (positive control) and DMSO
(negative control) were prepared with 2.5% v/v final
concentration. Two (2) sets of untreated controls for
compensation were also prepared accordingly and were
incubated at 37 °C for 24 hours. After incubation, 5 μL of
propidium iodide (5 µM) and 5 μL of SYTO 9 were added
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to each treatment. For the compensation controls, one set
of the untreated cells was stained with 5 μL of propidium
iodide (5 µM), while another set of untreated cells was
stained with 5 μL of SYTO 9 and incubated at 37 °C for
30 minutes in the dark. Afterward, the treated cells were
harvested and washed twice by centrifugation (8,000
rpm for 5 minutes) and resuspended in 200 μL of PBS.
Antiproliferative activity of the crude extracts was
determined through intensiometric measurement using
an Amnis Flow Sight imaging flow cytometer (AF-IFC)
(Merck, USA). The AF-IFC system was calibrated,
cleaned, and sterilized (sample lines). Each prepared
seed suspension was then run in the AF-IFC and data
acquisition was made using the INSPIRE ImageStreamX
MKII software. The object count was set at 5000. The
gating strategy for S. cerevisiae was adopted from the
protocol of Patterson et al. (2015). All data acquired
using the AF-IFC INSPIRE software were subjected to
a gating (selecting) strategy, which mainly involved the
following parameters: brightfield gradient root mean
squared feature (Gradient RMS_M01_Ch01), brightfield
area feature (Area_M01), brightfield aspect ratio feature
(Aspect Ratio_M01), and fluorescence channel 5
(Intensity_MC_Ch05). Area values of 50-600 and Aspect
ratio values of 0.4-1.0 were used to select S. cerevisiae
cells. Crude extracts yielding >50% antiproliferative
activity or more were considered active. The gated cell
population was then graphed using a histogram with
the Y-axis designating the cell count and the X-axis
designating the fluorescence intensity reading in channel
5 (642-740 nm). Channel 5 fluorescence reading of more
than 100 was considered characteristic of dead cells
(Kamaruddin et al., 2019).
Budding yeast analysis
The effects of the crude extracts on the cell cycle of
the yeast cells were determined through the budding
yeast analysis. This is a post-hoc method from the
images acquired by the imaging flow cytometer from
the antiproliferative assay. Unbudded cells are in the
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G1 phase, small-budded cells are in the S phase, and
large-budded cells are in the G2/M phase of the cell
cycle (Sanchez-pico et al., 2014). Cell counts for the
respective morphologies were analyzed using Image
Data Exploration and Analysis Software (IDEAS).
The different budding morphologies of the yeast were
differentially grouped using the Area_M01 and Aspect
Ratio_M01 features of the AF-IFC.
Statistical analysis
One-way analysis of variance was used to determine
the significant difference between treatments in
antiproliferative activity and live/dead assay. Post-hoc
analysis Tukey HSD was used to determine pairwise
differences between treatments. Analysis was considered
significant if the p-value <0.05.
RESULTS AND DISCUSSION
Currently, the most extensively investigated microbial
source of marine natural products involves bacteria
isolated from marine sediments (Perez & Fenical, 2017).
These marine sediment-derived microbes, particularly
Actinomycetes, have been thoroughly studied, yielding
numerous novel and unprecedented new chemical
structures and potentiating the discovery of new
drugs with a novel mechanism of action (Blunt et al.,
2013). Actinomycetes are widely known to produce
antiproliferative compounds in several structural classes,
such as anthracyclines, enediynes, indocarbazoles,
isoprenoides, macrolides, non-ribosomal peptides, and
others (Sabido et al. 2020). The antiproliferative activity
of these metabolites involves the induction of apoptosis
through topoisomerase I or II inhibition, mitochondrial
permeabilization, and inhibition of key enzymes involved
in cell signal transduction (Karthikeyan et al., 2022).
Interestingly, our findings in the current study corroborate
the previous findings regarding the antiproliferative
activity of crude extract from a marine sediment-derived

Figure 1. Streptomyces sp. Strain DSD011, DSD017, and DSD042 (left to right) grown in
marine media (Sabido et al. 2021)
E-ISSN 2477-0612
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Figure 2. Percentage (%) growth inhibition of S. cerevisiae in the selected treatments
and control. Concentration of Triton x is at 2.5% v/v while the rest of the treatments
(isolates) are at 2500 µg/ml. The broken red line designates the 50% level for growth
inhibition that is used as indicator if the isolate is bioactive as an antiproliferative
agent or not. Values of % growth inhibition indicated are mean ± standard deviation
(SD), n=3. (*) = significant difference with positive control (Triton-X) (p<0.05) using
Tukey HSD. Negative control (DMSO) was excluded in the comparison.

Figure 3. Representative scatterplot graphs for the fluorescence intensity emitted by the
treated yeast cells in Channel 2 (505-560 nm) and Channel 5 (642-740 nm). The X-axis
and Y-axis plot the fluorescence intensity of cells stained with SYTO 9 and propidium
iodide, respectively. Population regions labelled in red and blue represent dead and live
cells, respectively. The treatments in the experiment are as follows: (A) DMSO (negative
control), (B) Triton X (final concentration at 2.5% v/v), and (C) DSD011 (2500 µg/ml).
E-ISSN 2477-0612
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Actinomycete. The antiproliferative activity of the crude
extracts of select marine sediment-derived Actinomycetes
(Figure 1) was determined using the budding yeast
S. cerevisiae as a model organism (Patterson et al.,
2015). S. cerevisiae is widely used in investigating cell
cycle regulation, which is dysfunctional in cancer cells
(Menacho-Marquez & Murguia, 2007). This makes S.
cerevisiae an invaluable tool for the early stages of cancer
drug discovery. Using a modified broth microdilution
assay, the results showed that out of the three crude
extracts (DSD011, DSD017, and DSD042), only
DSD011 could inhibit more than 50% of the growth of S.
cerevisiae (Figure 2). This average percentage inhibition
of DSD011 at the concentration 2500 µg/ml (86.1% ±
2.7%) was comparable to that of the positive control
Triton X at the concentration 2.5% v/v (93.3% ±1.5%.
The high inhibitory activity of the DSD011 extract
against S. cerevisiae warrants further investigation
regarding its antiproliferative action mechanism and its
target component of the cell cycle regulation.
Since the antiproliferative activity of DSD011 was
comparable to Triton-X, we suggest that this compound
might target the yeast’s cell membrane or molecular
systems responsible for cell cycle regulation. Therefore,
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further assessment through live/dead assay using imaging
flow cytometry was performed utilizing a mixture of two
fluorescent dyes: SYTO 9 and propidium iodide. SYTO 9
is a membrane-permeable dye that stains cells with intact
membranes (viable cells) and emits green fluorescence
at around 505-515 nm. On the other hand, propidium
iodide is a membrane-impermeable dye that can only
pass through the perforated or lysed membrane and
fluorescing red at around 600-610 nm as it intercalates
with DNA (Robertson et al., 2019). The uptake of
propidium iodide and SYTO 9 by treated S. cerevisiae
cells were visualized using Amnis Flow Sight imaging
flow cytometer (AF-IFC) through detection channels 2
and 5 for emissions of SYTO 9 and propidium iodide,
respectively. Live and dead cells were initially analyzed
(Figure 3), with the majority (>50%) of S. cerevisiae
cells treated with DMSO (negative control) being found
to be alive (fluorescing at 505-560 nm), indicating living
cells. In contrast, more than 50% of S. cerevisiae cells
fluoresced at channel 5 (642-740 nm) when treated with
Triton X and DSD011 extract, indicating dead cells
caused by a damaged cell membrane.
Results of the live/dead assay of the treatments against
S. cerevisiae are shown in Figure 4, and the percentage

Figure 4. Live/dead assay shows % population of necrotic (dead) cell and
live cells. The broken red line indicates 50% of the population percentage.
Treatments with 50% dead S. cerevisiae population are considered
antiproliferative. Values indicated are mean±standard deviation. n=3
Table 1. Percentage live/dead cell assay to the treatment groups

Live
Dead

DMSO

Triton-X

DSD011

p

86.73%±5.84%
11.75%±5.21%

29.43%±9.13%
70.53%±9.17%

33.87%±11.48%
62.90%±10.93%

<0.001*
<0.001*

Data presented in mean±SD. Treatments for live and dead cells were separately analysed using One-way
ANOVA. (*) = significant difference with positive control (Triton-X) (p<0.001) using Tukey HSD
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Table 2. One-way Analysis of Variance (ANOVA) table for percentage live/dead cell assay

Live Cells
Dead Cells

Between Groups
Within Groups
Between Groups
Within Groups

df

Mean Square

F

Sig.

2
6
2
6

3048.914
124.600
3065.035
115.429

24.470

0.001

26.554

0.001

Groups: Negative control (DMSO), Positive control (Triton-X), and DSD011 extract. Difference between groups for
both live and dead cells were significant (p<0.001)

of comparison between crude extract DSD011 and the
negative control (DMSO) and positive control (Triton X)
is shown in Table 1. The percentage of live/dead cells in
the treatments was normally distributed as assessed by
Shapiro-Wilk’s test (Live p = 0.128, Dead p = 0.086).
There were no significant differences in the variance
among treatment and controls with Levene statistic in
terms of live cells (2, 6) = 0.816, p = 0.486, and dead
cells with (2, 6)=1.184, p = 0.369. With homogenous
variances, the results were analyzed using parametric
one-way analysis of variance (ANOVA). In Table 2,
live and dead cells among the treatment group and
controls were found to be significantly different from
F(2, 6)=24.470, p < 0.001, and F(2, 6)=26.554, p <
0.001, respectively. Post-hoc analysis Tukey showed
that for both the live and dead cell populations, DMSO
was significantly different from Triton X and DSD011.
Remarkably, the mean percentage of live and dead cell
populations in Triton X and DSD011 was not significantly
different from the mean difference (-4.433), p = 0.0880,
and mean difference (7.633), p = 0.677, respectively. The
comparable live/dead population of S. cerevisiae cells
treated with DSD011 extract to that of Triton X showed
that compounds present in the extract directly kill cells
instead of putting their growth into stasis.
From what we found, marine sediment of crude
extract DSD011 was found to possess a measurable
antiproliferative effect against S. cerevisiae. Taken
together, this result confirms the antiproliferative activity
of crude extracts of other marine sediment-derived
Actinomycete strains, which were also reported by other
researchers using different cancer cell lines (Chen et al.,
2018). Diverse secondary metabolites were responsible
for the potent anticancer and antiproliferative activities
of extracts from marine sediment-derived Actinomycetes
(Sabido et al., 2020). The presence of secondary
metabolite biosynthetic gene clusters (SMBGCs) in
marine actinobacteria allows them to synthesize various
natural products, including alkaloids (Chen et al., 2019),
polyketides (Lu et al., 2020), peptides (Joseph et al.
2021), isoprenoids (McKinnie et al., 2018), phenazines
(Sletta et al., 2014), and their derivatives. Moreover,
the vast array of extractable bioactive compounds from
marine Actinomycetes potentiates it as a new source of
E-ISSN 2477-0612

drugs against different types of cancers. Therefore, it
is inferred that the crude extract of DSD011 contains
potential anticancer compounds, which warrants further
tests for antiproliferative activity.
The antiproliferative activity of the bioactive crude
extract (DSD011) was further assessed using budding
yeast analysis. S. cerevisiae divides by budding, with
each budding phase reflecting different cell cycle stages.
Budding yeast possesses cellular processes that are
remarkably homologous to mammalian cells (Matuo
et al., 2012). Eukaryotic cellular components such as
actin (Akram et al., 2020) and telomerases (Armstrong
& Tomita, 2017) are highly conserved between yeasts
and human cells. Furthermore, S. cerevisiae is costeffective to grow and maintain, making it a spectacular
model for the preliminary screening compounds with
antiproliferative activity. This is in contrast to the high
cost and maintenance of using human and mammalian
cell lines. With respect to the cell cycle, unbudded
cells are in the G1 phase, small-budded cells are in the
S phase, and large-budded cells are in the G2/M phase
(Figure 5). The S. cerevisiae cells treated with the crude
extract of DSD011 exhibited a disrupted cellular growth
cycle, especially in the G1 phase, as seen in the increased
number of unbudded cells. This further supports the
hypothesis that the anticancer compounds in the crude
extract of DSD011, which caused dysregulation of the
cell cycle of S. cerevisiae, are highly specific to proteins
and molecular signals responsible for the initiation of
the cell cycle. It is hypothesized that antiproliferative
compounds in the extracts target proteins and molecular
signals responsible for the initiation of DNA replication
(Lee & Jeong, 2020). Furthermore, the number of
abnormal or multibudded cells that were treated by
DMSO and DSD011 were almost equal, unlike that of the
positive control (Triton X), suggesting the mechanism of
action of the compounds present in the crude extracts of
DSD011 targets specific checkpoints or molecules in the
cell cycle of S. cerevisiae.
The antiproliferation mechanism of DSD011 extract
might be explained through various anticancer
mechanisms observed from previously discovered
compounds present in marine sediment-derived
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Figure 5. Percent count summary of the different budding phases of S. cerevisiae treated with the crude
extract of DSD011, DMSO (negative control), and Triton X (positive control) (n=3). Representative image
from the imaging flow cytometer are provided in each panel
Actinomycetes, such as salinosporamide A (SerranoAparicio et al., 2003), fijolides A (Rudolf et al., 2016),
and proximicin C (Brucoli et al., 2012). Salinosporamide
A, isolated from the marine sediment actinomycete
Salinispora tropica, is widely reported as a novel 20S
proteasome inhibitor. Salinosporamide A possesses a
densely functionalized γ-lactam-β-lactone bicyclic core
that allows it to irreversibly bind to the β subunit of the
20S proteasome (Serrano-Aparicio et al., 2003). Recently,
salinosporamide A in experimentally determined
concentrations was found to regulate the proliferation
and entry of Jurkat T cells to the G2/M phase of the cell
cycle (Lee & Jeong, 2020). Meanwhile, fijiolides A, a
potent antitumor compound isolated from Nocardiopsis
sp. (Nam et al., 2010), is a profound inhibitor of tumor
necrosis factor (TNF-α)-induced activation of nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-κB). Inactivated NF-κB results in cell proliferation
arrest by inhibiting the transcription of genes needed
for cell proliferation and survival (Chen et al., 2019).
Proximicin C, another antitumor compound isolated
from a marine sediment Actinomycete, Verrucosispora
sp. (Brucoli et al., 2012), is known to inhibit cell
proliferation of different cancer cell lines through the
upregulation of the tumor protein p53 and cyclin kinase
inhibitor p21, which plays a critical role in the G1/S
checkpoint (Sharma & Nandi et al., 2022). The arrest of
S. cerevisiae cells in the G1 phase suggests that the crude
extract of DSD011 may possess secondary metabolites
with similar structures and mechanisms of action to that
of the previously discussed, which were also isolated
from marine sediment-derived Actinomycetes.

against human cancer cell lines as well as metabolomics
and genomics profiling to elucidate the secondary
metabolites and SMBGCs present in the extract, are
required for a comprehensive understanding of the
potential anticancer activity.

This study demonstrates that marine sediments in
the Philippines harbor Actinomycetes that produce
antiproliferative compounds. Nevertheless, further
works, including in vitro testing of the DSD011 extract
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CONCLUSION
The challenge of discovering new chemotherapeutic
compounds was taken through the screening of crude
extracts of select marine sediment-derived Actinomycetes
from Islas de Gigantes, Iloilo. One marine sedimentderived Actinomycete crude extract (DSD011) was
found to possess antiproliferative activity by inhibiting
the growth of S. cerevisiae. The antiproliferative activity
of DSD011 was further demonstrated when S. cerevisiae
cells were treated with its extract lysed, as seen in live/
dead imaging flow cytometry results. Furthermore, the
budding yeast analysis results suggest that the crude
extracts of DSD011 possess secondary metabolites that
target the initiation checkpoints for the G1/S phase in the
cell cycle.
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